A Dark Vector Cognition product

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

57K characters. Original on sec.gov ·

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities

Litigation Reform Act of 1995, we

provide the following cautionary remarks regarding important factors

that, among others, could cause future results

to differ materially from the forward-looking statements, expectations and assumptions

expressed or implied herein.

All forward-looking statements made by us are subject to risks and uncertainties

and are not guarantees of future

performance.

These forward-looking statements involve known and unknown

risks, uncertainties and other factors

that may cause our actual results, performance and achievements

or industry results to be materially different from

any future results, performance or achievements expressed or implied

by such forward-looking statements.

These

statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,”

“plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to

make” or other comparable terms.

Factors that

could cause or contribute to such differences include, but are not limited to,

those discussed in the documents we

file with the Securities and Exchange Commission (SEC), including our Annual

Report on Form 10-K, and will be

contained in subsequent periodic filings we make with the SEC.

These documents identify in detail important risk

factors that could cause our actual performance to differ materially from current

expectations.

Risk factors and uncertainties that could cause actual results to differ materially from

current and historical results

include, but are not limited to: our dependence on third parties for

the manufacture and supply of our products and

where we manufacture products, our dependence on third parties

for raw materials or purchased components; risks

relating to the achievement of our strategic growth objectives, including

anticipated results of restructuring and

value creation initiatives; risks related to the Strategic Partnership Agreement with

KKR Hawaii Aggregator L.P.

entered into in January 2025; transitions in senior company leadership

(including, without limitation, our Chief

Executive Officer, Chief Financial Officer, and other executive officers); our ability to develop or acquire and

maintain and protect new products (particularly technology and specialty

products) and services and utilize new

technologies that achieve market acceptance with acceptable margins; transitional

challenges associated with

acquisitions and joint ventures, including the failure to achieve anticipated

synergies/benefits, as well as significant

demands on our operations, information systems, legal, regulatory, compliance, financial and human resources

functions in connection with acquisitions, dispositions and joint ventures; certain

provisions in our governing

documents that may discourage third-party acquisitions of us; adverse changes

in supplier rebates or other

purchasing incentives; risks related to the sale of corporate brand products;

risks related to activist investors;

security risks associated with our information systems and technology

products and services, such as cyberattacks

or other privacy or data security breaches (including the October 2023 incident);

effects of a highly competitive

(including, without limitation, competition from third-party online commerce sites)

and consolidating market;

political, economic and regulatory influences on the health care

industry; risks from expansion of customer

purchasing power and multi-tiered costing structures; increases in shipping costs

for our products or other service

issues with our third-party shippers, and increases in fuel and energy costs; changes

in laws and policies governing

manufacturing, development and investment in territories and countries

where we do business; general global and

domestic macro-economic and political conditions, including inflation,

deflation, recession, unemployment (and

corresponding increase in under-insured populations), consumer confidence,

sovereign debt levels, fluctuations in

energy pricing and the value of the U.S. dollar as compared to foreign currencies

and changes to other economic

indicators; failure to comply with existing and future regulatory

requirements, including relating to health care;

risks associated with the EU Medical Device Regulation; failure to comply with

laws and regulations relating to

health care fraud or other laws and regulations; failure to comply with

laws and regulations relating to the

collection, storage and processing of sensitive personal information or standards

in electronic health records or

transmissions; changes in tax legislation, changes in tax rates and availability

of certain tax deductions; risks related

to product liability, intellectual property and other claims; risks associated with customs policies or legislative

import restrictions; risks associated with disease outbreaks, epidemics,

pandemics (such as the COVID-19

pandemic), or similar wide-spread public health concerns and other

natural or man-made disasters; risks associated

with our global operations; the threat or outbreak of war (including, without

limitation, geopolitical wars), terrorism

or public unrest (including, without limitation, the wars in Ukraine

and Iran, the Israel-Gaza conflict and other

unrest and threats in the Middle East and the possibility of a wider European

or global conflict); changes to laws

and policies governing foreign trade, tariffs and sanctions or greater restrictions on

imports and exports, including

changes to international trade agreements and the current imposition of

(and the potential for additional) tariffs by

the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation

risks; new or unanticipated

litigation developments and the status of litigation matters; our dependence

on our senior management, employee

hiring and retention, increases in labor costs or health care costs, and our

relationships with customers, suppliers

and manufacturers; and disruptions in financial markets.

The order in which these factors appear should not be

construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control

or predict.

Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction

of actual results.

We undertake no duty and have no obligation to update forward-looking statements except as

required by law.

Where You

Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public

conference calls and webcasts, press releases, the investor relations

page of our website (www.henryschein.com)

and the social media channels identified on the About Media Center page

of our website.

Recent Developments

Chief Financial Officer

On October 8, 2026, we announced that, effective November 4, 2026, Ronald N.

South will transition from his

position as Senior Vice President and Chief Financial Officer to the role of Senior Advisor.

Emmanuel Caprais,

Senior Financial Advisor as of October 12, 2026, will succeed Mr. South as Chief Financial Officer effective

November 4, 2026.

Tariffs and Related Economic Conditions

The U.S. has adopted new and increased tariffs on imports from countries, and

the scope, applicability and legal

basis for these tariffs continue to evolve through legislative and executive

actions, exemptions and ongoing judicial

challenges.

Although the U.S. Supreme Court invalidated certain tariffs imposed

under the International

Emergency Economic Powers Act (IEEPA), the U.S. government has subsequently implemented additional tariff

measures under other statutory authorities, and further changes to U.S. trade policy

remain possible.

Some

countries have imposed, or may impose, retaliatory tariffs or other restrictions on imports

from the U.S.

These

developments, and anticipated future developments, have created a

volatile environment for global trade, and new

trade policies with individual countries.

It is unclear whether, or the extent to which, the current tariffs on trade

with numerous countries will remain in place, or change, the exceptions

that may apply, and their timing.

The tariffs did not have an adverse material impact on our results of operations during

fiscal year 2025 and the nine

months ended September 26,

2026, although sales of U.S. dental equipment were temporarily impacted

by market

uncertainty related to tariffs in the second half of the quarter ended June 28, 2025.

During the three and nine months ended September 26, 2026, we

recognized a net benefit of $28 million and $30

million, respectively, related to previously paid IEEPA tariffs.

We expect to recognize additional benefit from

tariff refunds during the fourth quarter of 2026.

Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered

by a network of people and

technology.

We

believe we are the world’s largest provider of health care products and services primarily to office-

based dental and medical practitioners, as well as alternate sites of care.

We

serve more than one million customers

worldwide including dental practitioners, laboratories, physician practices and

ambulatory surgery centers, as well

as government, institutional health care clinics, home health providers, and

other alternate care clinics.

We

believe

that we have a strong brand identity due to our more than 94 years of experience

distributing health care products.

We

are headquartered in Melville, New York, employ approximately 25,000 people (of which more than 13,000 are

based outside of the United States) and have operations or affiliates in 34 countries and

territories.

Our broad

global footprint has evolved over time through our organic growth as well as through

contribution from strategic

acquisitions.

We

have established strategically located distribution centers around

the world to enable us to better serve our

customers and increase our operating efficiency.

This infrastructure, together with broad product and service

offerings at competitive prices, and a strong commitment to customer service, enables

us to be a single source of

supply for our customers’ needs.

As a distributor, we market and sell branded products as well as our own corporate brand portfolio of

cost-effective,

high-quality consumable merchandise products.

We

also manufacture, source and sell a range of company-owned

manufactured products, primarily implants, biomaterial products, endodontics, handpiece

and small equipment,

hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products.

We

have

achieved scale in these global businesses primarily through acquisitions, as

manufacturers of these products

typically do not utilize a distribution channel to serve customers.

Our reportable segments consist of: (i) Global Distribution and Value-Added Services; (ii) Global Specialty

Products; and (iii) Global Technology.

Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of

national brand and corporate brand merchandise, as well as equipment and related

technical services.

This segment

also includes value-added services such as financial services, continuing education

services, consulting and other

services.

This segment also markets and sells under our own corporate brand,

a portfolio of cost-effective, high-

quality consumable merchandise.

Global Specialty Products includes manufacturing, marketing

and sales of dental

implant and biomaterial products; and endodontic, orthodontic and orthopedic

products and other health care-

related products and services.

Global Technology includes development and distribution of practice management

software, e-services and other products, which are distributed to health

care providers.

A key element to grow closer to our customers is our One Schein initiative, which

is a unified go-to-market

approach that enables practitioners to work synergistically with our supply chain, equipment

sales and service and

other value-added services, allowing our customers to leverage the

combined value that we offer through a single

program.

Specifically, One Schein provides customers with streamlined access to our comprehensive offering of

national brand products, corporate brand products and proprietary specialty products

and solutions (including

implant, orthodontic and endodontic products).

In addition, customers have access to a wide range of services,

including software and other value-added services.

Industry Overview

In recent years, the health care industry has increasingly focused on cost containment.

This trend has benefited

distributors capable of providing a broad array of products and services at low

prices.

It also has accelerated the

growth of DSOs, GPOs, HMOs, group practices, other managed care

accounts and collective buying groups, which,

in addition to their emphasis on obtaining products at competitive prices,

tend to favor distributors capable of

providing specialized management information support.

We

believe that the trend towards cost containment has

the potential to favorably affect demand for technology solutions, including software and

Artificial Intelligence

solutions, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies

and transactions that we

undertook to expand our business, domestically and internationally, in part to address significant changes in the

health care industry, including consolidation of health care distribution companies, health care reform, trends

toward managed care, cuts in Medicare and collective purchasing arrangements.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented

and diverse.

The industry ranges from sole practitioners working out of

relatively small offices to group practices

or service organizations ranging in size from a few practitioners to a large number of practitioners who have

combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage

large quantities of supplies

in their offices, the distribution of health care supplies and small equipment to office-based health

care practitioners

has been characterized by frequent, small quantity orders, and a need for rapid,

reliable and substantially complete

order fulfillment.

The purchasing decisions within an office-based health care practice are typically

made by the

practitioner or an administrative assistant.

Supplies and small equipment are generally purchased from more

than

one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base.

Health care practitioners are increasingly seeking to

partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician

hospital organizations.

In many cases, purchasing decisions for consolidated groups are

made at a centralized or

professional staff level; however, orders are delivered to the practitioners’ offices.

Our approach to acquisitions and joint ventures has been to expand our role as

a provider of products and services

to the health care industry.

This trend has resulted in our expansion into service areas that complement

our existing

operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired

businesses.

As industry consolidation continues, we believe that we are positioned

to capitalize on this trend, as we believe we

have the ability to support increased sales through our existing infrastructure, although

there can be no assurances

that we will be able to successfully accomplish this.

We

are focused on building relationships with decision makers

who do not reside in the office-based practitioner setting.

As the health care industry continues to change, we intend to continue to

seek opportunities to expand our role as a

provider of products and services to the health care industry.

There can be no assurance that we will be able to

successfully pursue any such opportunity or consummate any such transaction,

if pursued.

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth

due to the aging population,

increased health care awareness, the proliferation of medical technology

and testing, new pharmacological

treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment

on

insurance coverage.

In addition, the physician market continues to benefit from the

shift of procedures and

diagnostic testing from acute care settings to alternate-care sites, particularly

physicians’ offices.

According to the U.S. Census Bureau’s International Database, between 2026 and 2036, the 45 and older

population is expected to grow by approximately 10%.

Between 2026 and 2046, this age group is expected to grow

by approximately 17%.

This compares with expected total U.S. population growth rates of

approximately 4%

between 2026 and 2036

and approximately 6% between 2026 and 2046.

According to the U.S. Census Bureau’s International Database, in 2026 there are over seven million Americans

aged 85 years or older, the segment of the population most in need of long-term care and elder-care services.

By

the year 2050, that number is projected to increase to over 17 million.

The population aged 65 to 84 years is

projected to increase by approximately 12% during the same period.

As a result of these market dynamics, annual expenditures for health care services

continue to increase in the

United States.

We

believe that demand for our products and services will grow while

continuing to be impacted by

current and future operating, economic and industry conditions.

The Centers for Medicare and Medicaid Services,

or CMS, published “National Health Expenditure Data” indicating that

total national health care spending reached

approximately $5.3 trillion in 2024, or 18.0% of the nation’s gross domestic product, the benchmark measure

for

annual production of goods and services in the United States.

Health care spending is projected to reach

approximately $9.0 trillion by 2034, or 20.6% of the nation’s projected gross domestic product.

We

believe similar demographic changes are also occurring in other

markets we serve outside the U.S.

Government

Certain of our businesses involve the distribution, manufacturing, importation,

exportation, marketing, sale and/or

promotion of pharmaceuticals, medical devices and/or in vitro diagnostics

and in this regard, we are subject to

extensive local, state, federal and foreign governmental laws and regulations,

including as applicable to our

wholesale distribution of pharmaceuticals, medical devices, and in vitro diagnostics;

manufacturing activities; and

as part of our specialty home medical supplies businesses that distribute and sell

medical equipment and supplies

directly to patients.

Federal, state and certain foreign governments have also increased

enforcement activity in the

health care sector, particularly in areas of fraud and abuse, anti-bribery and anti-corruption, controlled substances

handling, medical device regulations and data privacy and security standards.

Certain of our businesses involve pharmaceuticals and/or medical devices,

including orthopaedic, in vitro

diagnostic devices, software regulated as a medical device, and sales of

medical equipment and supplies directly to

patients, that are paid for by third parties and/or patients and must operate in

compliance with a variety of

burdensome and complex coding, billing and record-keeping requirements

in order to substantiate claims for

payment under federal, state and commercial/private health care reimbursement

programs.

Government and private insurance programs fund a large portion of the total cost of medical

care, and there have

been efforts to limit such private and government insurance programs, including efforts, thus far

unsuccessful, to

seek repeal of the entire United States Patient Protection and Affordable Care Act,

as amended by the Health Care

and Education Reconciliation Act, each enacted in March 2010.

Certain of our businesses are subject to various additional federal, state,

local and foreign laws and regulations,

including with respect to the sale, transportation, importation, storage, handling

and disposal of hazardous or

potentially hazardous substances; “forever chemicals” such as per-and

polyfluoroalkyl substances; warnings related

to potential cancer or reproductive harm linked to chemicals; amalgam bans; pricing disclosures;

supply chain

transparency around human trafficking and forced labor practices; and safe working

conditions.

In addition,

activities to control medical costs, including laws and regulations lowering

reimbursement rates for

pharmaceuticals, medical devices, medical supplies and/or medical

treatments or services, are ongoing.

Laws and

regulations are subject to change and their evolving implementation may impact

our operations and financial

performance.

Certain of our businesses also maintain contracts with governmental agencies

and are subject to certain regulatory

requirements specific to government contractors.

Our businesses are generally subject to numerous laws and regulations that could

impact our financial performance,

and failure to comply with such laws or regulations could have a material

adverse effect on our businesses.

A more detailed discussion of laws, regulations and governmental activity

is included in Management’s Discussion

and Analysis of Financial Condition and Results of Operations, contained

in our Annual Report on Form 10-K for

the fiscal year ended December 27, 2025, filed with the SEC on February

24, 2026.

Results of Operations

The following tables summarize the significant components of our operating

results for the three and nine months

ended September 26, 2026 and September 27, 2025 and cash flows for the nine

months ended September 26, 2026

and September 27, 2025 (in millions):

Three Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2026

2025

2026

2025

Operating results:

Net sales

$

3,471

$

3,339

$

10,297

$

9,747

Cost of sales

2,366

2,313

7,021

6,705

Gross profit

1,105

1,026

3,276

3,042

Operating expenses:

Selling, general and administrative

2,459

2,276

Depreciation and amortization

Restructuring and related costs

Operating income

$

$

$

$

Other expense, net

$

(33)

$

(30)

$

(99)

$

(90)

Income taxes

(37)

(28)

(109)

(94)

Net income

Net income attributable to Henry Schein, Inc.

Nine Months Ended

September 26,

September 27,

2026

2025

Cash flows:

Net cash provided by operating activities

$

$

Net cash used in investing activities

(173)

(253)

Net cash provided by (used in) financing activities

(138)

Plan of Restructuring and Related Costs

On August 6, 2024, we committed to a restructuring plan (the “2024

Plan”) to integrate our acquisitions, right-size

operations and further increase efficiencies.

We currently expect this plan to be completed by the end of 2027.

During the three months ended September 26, 2026 and September 27, 2025,

we recorded restructuring and related

charges associated with the 2024 Plan of $22 million and $34 million, respectively.

During the nine months ended

September 26, 2026 and September 27, 2025, we recorded restructuring

charges associated with the 2024 Plan of

$63 million and $82 million, respectively.

The restructuring and related costs for these periods primarily related to

severance and employee-related costs, costs to exit facilities and other

exit costs.

We expect to record restructuring

and related charges associated with the 2024 Plan through the end of 2027; however,

an estimate of the amount of

these charges for 2026

through 2027 has not yet been determined.

During the nine months ended September 26, 2026,

in connection with the 2024 Plan, we recorded a loss of $2

million related to the disposal of businesses in the Global Specialty Products

segment.

This amount is included in

the $63 million of restructuring and related charges discussed above.

Three Months Ended September 26, 2026 Compared to Three Months Ended September 27, 2025

Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other

Expense, Net; and Income Taxes are

based on actual values and may not recalculate due to rounding.

Our reportable segments are determined based on how our Chief Executive

Officer manages the business, assesses

performance and allocates resources.

We have three reportable segments:

(i) Global Distribution and Value-Added

Services; (ii) Global Specialty Products; and (iii) Global Technology.

Net Sales

Net sales by reportable segment and by major product or service type were

as follows:

September 26,

% of

September 27,

% of

Increase/(Decrease)

2026

Total

2025

Total

$

%

Global Distribution and Value

-Added Services

Global Dental Merchandise

(1)

$

1,295

37.3

%

$

1,210

36.2

%

$

7.0

%

Global Dental Equipment

(2)

12.9

13.2

2.3

Global Value

-Added Services

(3)

1.8

1.9

(2)

(4.8)

Global Dental

1,806

52.0

1,714

51.3

5.4

Global Medical

(4)

1,138

32.8

1,126

33.8

1.1

Total Global Distribution and Value

-Added Services

2,944

84.8

2,840

85.1

3.7

Global Specialty Products

(5)

11.3

11.0

6.1

Global Technology

(6)

5.2

5.2

5.2

Eliminations

(45)

(1.3)

(43)

(1.3)

(2)

n/a

Total

$

3,471

100.0

%

$

3,339

100.0

%

$

4.0

(1)

Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum,

acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.

(2)

Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair

services and high-tech and digital restoration equipment.

(3)

Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.

(4)

Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-

control products, X-ray products, equipment, PPE products, and vitamins.

(5)

Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and

orthopedic products and other health care-related products and services.

(6)

Consists of the development and distribution of practice management software, e-services and other technology-enabled products

for health care providers.

The components of our sales growth were as follows:

Constant Currency

Growth/(Decline)

Total Constant

Currency

Growth/(Decline)

Foreign

Exchange

Impact

Total Sales

Growth/

(Decline)

Local Internal

Growth/(Decline)

Acquisition/

(Disposition)

Growth

Global Distribution and Value

-Added Services

Global Dental Merchandise

5.1

%

1.3

%

6.4

%

0.6

%

7.0

%

Global Dental Equipment

2.4

-

2.4

(0.1)

2.3

Global Value

-Added Services

(4.8)

-

(4.8)

-

(4.8)

Global Dental

4.1

0.9

5.0

0.4

5.4

Global Medical

1.0

-

1.0

0.1

1.1

Total Global Distribution and Value

-Added Services

2.9

0.5

3.4

0.3

3.7

Global Specialty Products

3.4

2.6

6.0

0.1

6.1

Global Technology

6.5

(1.3)

5.2

-

5.2

Total

3.1

0.7

3.8

0.2

4.0

Global Sales

Global net sales for the three months ended September 26, 2026 increased 4.0%,

attributable to internal growth of

3.1%, acquisition growth of 0.7%, and an increase in foreign exchange

of 0.2%.

The components of our sales

increase are presented in the table above.

Global Distribution and Value-Added Services Sales

Global Distribution and Value-Added Services net sales for the three months ended September 26, 2026 increased

3.7%.

The components of our sales increase are presented in

the table above.

The 4.1% increase in internally generated local currency dental sales was

primarily due to merchandise and

traditional equipment sales growth in the U.S. and merchandise and equipment

sales growth in international

markets.

The 1.0% increase in internally generated local currency medical sales was

attributable to growth of our Home

Solutions businesses,

partially offset by lower sales of point of care diagnostic test products and vaccines

related to

respiratory illness.

Global Specialty Products Sales

Global Specialty Products net sales for the three months ended September

26, 2026 increased 6.1%.

The

components of our sales increase are presented in the table above.

The 3.4% increase in internally generated local currency sales was attributable

to growth in our value and premium

implant businesses.

Global Technology Sales

Global Technology net sales for the three months ended September 26, 2026 increased 5.2%.

The components of

sales growth are presented in the table above.

The internally generated local currency increase of 6.5% in Global Technology sales was primarily attributable to

the increased rate of customer adoption of our core practice management solutions,

particularly our cloud-based

platforms, and a growth in revenue cycle management solutions.

Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

September 26,

Gross

September 27,

Gross

Increase/(Decrease)

2026

Margin %

2025

Margin %

$

%

Global Distribution and Value

-Added Services

$

25.8

%

$

24.7

%

$

8.0

%

Global Specialty Products

56.8

55.3

9.0

Global Technology

68.9

66.9

8.4

Corporate

-

n/a

n/a

(5)

n/a

Total

$

1,105

31.8

$

1,026

30.7

$

7.7

Gross margin may not be comparable to that of other distribution companies due to

differing industry practices in

the classification of distribution network costs.

Gross margin percentages also vary across our segments, reflecting

differences in business models.

The Global Specialty Products segment generates

higher gross margins, as it

primarily includes products we develop and manufacture, compared

to the Global Distribution and Value-Added

Services segment, which principally distributes third-party and corporate brand

products.

While the Global

Specialty Products segment has increasingly leveraged the Global

Distribution and Value-Added Services segment

as a sales channel, the impact on overall margins has not been material.

The Global Technology segment also

generates higher gross margins, reflecting our role as both developer and provider of

software products and

services.

Within our Global Distribution and Value

-Added Services segment, gross profit margins may fluctuate between the

periods as a result of the changes in product mix and customer mix.

With respect to customer mix, sales to our

large-group customers are typically completed at lower gross margins as a result of

higher sales volumes, while

sales to office-based practitioners generally carry higher gross margins due to lower volumes.

The increase in Global Distribution and Value-Added Services gross profit for the three months ended September

26, 2026 compared to the prior-year-period is due primarily to increased internally

generated sales volume as

described above.

During the three months ended September 26, 2026, in the Global

Distribution and Value-Added

Services segment, we recognized a net benefit of $20 million related to

refunds for certain IEEPA tariffs previously

paid in the United States.

In addition to the benefit of the tariff refunds, the increase in gross margin rates was

attributable primarily to favorable business mix and benefits from our value creation

initiatives.

The increase in Global Specialty Products gross profit primarily reflects

increased internally generated sales

volume and gross profit from acquisitions.

During the three months ended September 26, 2026, in the Global

Specialty Products segment, we recognized a net benefit of $8 million

related to refunds for certain IEEPA tariffs

previously paid in the United States.

In addition to the benefit of the tariff refunds, the increase in gross margin

rates was due to product mix.

The increase in Global Technology gross profit is the result primarily of higher internally generated sales.

The

increase in gross margin rates was due to product mix.

Operating Expenses

Operating expenses (consisting of selling, general and administrative

expenses; depreciation and amortization; and

restructuring and related costs) by segment were as follows:

% of

% of

September 26,

Respective

September 27,

Respective

Increase/(Decrease)

2026

Sales

2025

Sales

$

%

Global Distribution and Value

-Added Services

$

18.2

%

$

18.5

%

$

2.4

%

Global Specialty Products

42.5

36.0

25.4

Global Technology

39.7

40.3

3.7

Corporate

n/a

n/a

n/a

23.8

22.9

8.1

Adjustments

(1)

n/a

n/a

(12)

n/a

Total operating expenses

$

26.3

$

25.8

$

5.7

(1)

Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.

These

items may vary independently of business performance.

September 26,

September 27,

2026

2025

Adjustments:

Restructuring and related costs

$

$

Acquisition intangible amortization

Change in contingent consideration

Litigation settlements

Costs associated with shareholder advisory matters and select implementation related value

creation consulting costs

Total adjustments

$

$

The net increase in operating expenses was

attributable to the following:

Operating Costs

(excluding

acquisitions)

Acquisitions

Adjustments

Total

Global Distribution and Value

-Added Services

$

$

$

-

$

Global Specialty Products

-

Global Technology

-

-

Corporate

-

-

-

Adjustments

-

-

(12)

(12)

Total operating expenses

$

$

$

(12)

$

The components of the net increase in total operating expenses are presented

in the table above.

The increase in

operating costs (excluding acquisitions) during the three months ended

September 26, 2026 was primarily

attributable to costs associated with our sales growth.

During the three months ended September 27, 2025, our

operating costs were favorably impacted by a benefit of $28 million related

to the remeasurement to the fair value

of a previously held equity investment within our Global Specialty Products

segment.

Other Expense, Net

Other expense, net was as follows:

September 26,

September 27,

Variance

2026

2025

$

%

Interest income

$

$

$

-

(4.4)

%

Interest expense

(42)

(38)

(4)

(11.5)

Other, net

-

(1)

(86.5)

Other expense, net

$

(33)

$

(30)

$

(3)

(14.7)

Interest income during the three months ended September 26, 2026

included $2 million of a benefit related to

refunds of certain IEEPA tariffs previously paid in the United States.

Interest expense increased primarily due to

increased borrowings.

Income Taxes

Our effective tax rate was 23.1% for the three months ended September 26, 2026, compared

to 21.3% for the prior

year period.

The difference between our effective and federal statutory tax rates primarily relates to state and

foreign income taxes and interest expense.

For the three months ended September 27, 2025, the difference was

further impacted by the tax treatment associated with the acquisition of a controlling

interest of a previously held

non-controlling equity investment.

Nine Months Ended September 26, 2026 Compared to Nine Months Ended September

27, 2025

Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other

Expense, Net; and Income Taxes are

based on actual values and may not recalculate due to rounding.

Our reportable segments are determined based on how our Chief Executive

Officer manages the business, assesses

performance and allocates resources.

We have three reportable segments: (i) Global Distribution and Value

-Added

Services; (ii) Global Specialty Products; and (iii) Global Technology.

Net Sales

Net sales by reportable segment and by major product or service type were

as follows:

September 26,

% of

September 27,

% of

Increase/(Decrease)

2026

Total

2025

Total

$

%

Global Distribution and Value

-Added Services

Global Dental Merchandise

(1)

$

3,924

38.1

%

$

3,613

37.1

%

$

8.6

%

Global Dental Equipment

(2)

1,322

12.8

1,263

13.0

4.7

Global Value

-Added Services

(3)

1.8

1.8

3.1

Global Dental

5,426

52.7

5,050

51.9

7.4

Global Medical

(4)

3,268

31.7

3,197

32.8

2.2

Total Global Distribution and Value

-Added Services

8,694

84.4

8,247

84.7

5.4

Global Specialty Products

(5)

1,207

11.7

1,122

11.5

7.6

Global Technology

(6)

5.2

5.1

6.8

Eliminations

(139)

(1.3)

(124)

(1.3)

(15)

n/a

Total

$

10,297

100.0

%

$

9,747

100.0

%

$

5.6

(1)

Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum,

acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.

(2)

Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair

services and high-tech and digital restoration equipment.

(3)

Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.

(4)

Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-

control products, X-ray products, equipment, PPE products, and vitamins.

(5)

Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and

orthopedic products and other health care-related products and services.

(6)

Consists of the development and distribution of practice management software, e-services and other technology-enabled products

for health care providers.

The components of our sales growth/(decline) were as follows:

Constant Currency

Growth/(Decline)

Total Constant

Currency Growth

Foreign

Exchange

Impact

Total Sales

Growth

Local Internal

Growth

Acquisition/

(Disposition)

Growth

Global Distribution and Value

-Added Services

Global Dental Merchandise

4.7

%

1.3

%

6.0

%

2.6

%

8.6

%

Global Dental Equipment

2.7

-

2.7

2.0

4.7

Global Value

-Added Services

1.8

0.6

2.4

0.7

3.1

Global Dental

4.1

0.9

5.0

2.4

7.4

Global Medical

2.0

0.1

2.1

0.1

2.2

Total Global Distribution and Value

-Added Services

3.3

0.6

3.9

1.5

5.4

Global Specialty Products

2.6

2.7

5.3

2.3

7.6

Global Technology

7.5

(1.3)

6.2

0.6

6.8

Total

3.4

0.7

4.1

1.5

5.6

Global Sales

Global net sales for the nine months ended September 26, 2026

increased 5.6%, attributable to internal growth of

3.4%, acquisition growth of 0.7%, and an increase in foreign exchange

of 1.5%.

The components of our sales

increase are presented in the table above.

Global Distribution and Value-Added Services Sales

Global Distribution and Value-Added Services net sales for the nine months ended September 26, 2026 increased

5.4%.

The components of our sales increase are presented in

the table above.

The 4.1% increase in internally generated local currency dental sales was

primarily due to merchandise sales

growth in U.S. and international markets, growth in traditional dental equipment

in the U.S. and international

markets, partially offset by decreased sales in value-added services attributable to lower

brokerage revenue.

The 2.0% increase in internally generated local currency medical sales was

attributable to growth of our Home

Solutions business and dialysis products, partially offset by lower sales of point of

care diagnostic test products and

vaccines related to respiratory illness.

Global Specialty Products Sales

Global Specialty Products net sales for the nine months ended September

26, 2026 increased 7.6%.

The

components of our sales increase are presented in the table above.

The 2.6% increase in internally generated local currency sales was attributable

to growth in our value implant,

premium implant and biomaterial businesses.

Global Technology Sales

Global Technology net sales for the nine months ended September 26, 2026 increased 6.8%.

The components of

sales growth are presented in the table above.

The internally generated local currency increase of 7.5% in Global Technology sales was primarily attributable to

the increased rate of customer adoption of our core practice management solutions,

particularly our cloud-based

platforms as well as an increase in revenue cycle management solutions.

Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

September 26,

Gross

September 27,

Gross

Increase/(Decrease)

2026

Margin %

2025

Margin %

$

%

Global Distribution and Value

-Added Services

$

2,234

25.7

%

$

2,071

25.1

%

$

7.9

%

Global Specialty Products

55.9

55.4

8.7

Global Technology

69.1

67.5

9.2

Corporate

(3)

n/a

n/a

(14)

n/a

Total

$

3,276

31.8

$

3,042

31.2

$

7.7

Gross margin may not be comparable to that of other distribution companies due to

differing industry practices in

the classification of distribution network costs.

Gross margin percentages also vary across our segments, reflecting

differences in business models.

The Global Specialty Products segment generates

higher gross margins, as it

primarily includes products we develop and manufacture, compared

to the Global Distribution and Value-Added

Services segment, which principally distributes third-party and corporate brand

products.

While the Global

Specialty Products segment has increasingly leveraged the Global

Distribution and Value-Added Services segment

as a sales channel, the impact on overall margins has not been material.

The Global Technology segment also

generates higher gross margins, reflecting our role as both developer and provider of

software products and

services.

Within our Global Distribution and Value

-Added Services segment, gross profit margins may fluctuate between the

periods as a result of the changes in product mix and customer mix.

With respect to customer mix, sales to our

large-group customers are typically completed at lower gross margins as a result of

higher sales volumes, while

sales to office-based practitioners generally carry higher gross margins due to lower volumes.

The increase in Global Distribution and Value-Added Services gross profit for the nine months ended September

26, 2026 compared to the prior-year-period is due primarily to increased internally

generated sales volume as

described above.

During the nine months ended September 26, 2026, in the Global

Distribution and Value-Added

Services segment, we recognized a net benefit of $21

million related to refunds for certain IEEPA tariffs previously

paid in the United States.

In addition to the benefit of the tariff refunds, the increase in gross

margin rates was

attributable primarily to favorable business mix and benefits from our value

creation initiatives.

The increase in Global Specialty Products gross profit primarily reflects

increased internally generated sales

volume and gross profit from acquisitions.

During the nine months ended September 26, 2026, in

the Global

Specialty Products segment, we recognized a net benefit of $9 million related

to refunds for certain IEEPA tariffs

previously paid in the United States.

In addition to the benefit of the tariff refunds, the increase in gross margin

rates was due to product mix.

The increase in Global Technology gross profit is the result primarily of higher internally generated sales.

The

increase in gross margin rates was due to product mix.

Operating Expenses

Operating expenses (consisting of selling, general and administrative

expenses; depreciation and amortization; and

restructuring and related costs) by segment were as follows:

% of

% of

September 26,

Respective

September 27,

Respective

Increase

2026

Sales

2025

Sales

$

%

Global Distribution and Value

-Added Services

$

1,649

19.0

%

$

1,567

19.0

%

$

5.2

%

Global Specialty Products

41.3

39.4

13.0

Global Technology

41.4

41.1

7.6

Corporate

n/a

n/a

n/a

2,494

24.2

2,325

23.9

7.3

Adjustments

(1)

n/a

n/a

n/a

Total operating expenses

$

2,730

26.5

$

2,552

26.2

$

7.0

(1)

Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.

These

items may vary independently of business performance.

September 26,

September 27,

2026

2025

Adjustments:

Restructuring and related costs

$

$

Acquisition intangible amortization

Cyber incident-insurance proceeds, net of third-party advisory expenses

-

(20)

Change in contingent consideration

-

Litigation settlements

Impairment of intangible assets

-

Costs associated with shareholder advisory matters and select implementation related value

creation consulting costs

Total adjustments

$

$

The net increase in operating expenses was

attributable to the following:

Operating Costs

(excluding

acquisitions)

Acquisitions

Adjustments

Total

Global Distribution and Value

-Added Services

$

$

$

-

$

Global Specialty Products

-

Global Technology

-

-

Corporate

-

-

-

Adjustments

-

-

Total operating expenses

$

$

$

$

The components of the net increase in total operating expenses are presented

in the table above.

The increase in

operating costs (excluding acquisitions) during the nine months ended September

26, 2026 was primarily

attributable to costs associated with our sales growth and the unfavorable impact

of foreign exchange rates.

During

the nine months ended September 26, 2026, our operating costs were

impacted by a benefit of $11 million related to

remeasurement to the fair value of a previously held equity investment within our

Global Specialty Products

segment.

During the nine months ended September 27, 2025, our operating costs

were impacted by a benefit of

$28 million related to remeasurement to the fair value of a previously held

equity investment within our Global

Specialty Products segment and a $4 million benefit within our Global

Distribution and Value-Added Services

segment.

Other Expense, Net

Other expense, net was as follows:

September 26,

September 27,

Variance

2026

2025

$

%

Interest income

$

$

$

-

(1.5)

%

Interest expense

(124)

(111)

(13)

(11.5)

Other, net

(3)

(113.3)

Other expense, net

$

(99)

$

(90)

$

(9)

(10.5)

Interest income during the nine months ended September 26, 2026 included

$2 million of a benefit related to

refunds of certain IEEPA tariffs previously paid in the United States.

Interest expense increased primarily due to

increased borrowings.

Income Taxes

Our effective tax rate was 24.5% for the nine months ended September 26, 2026, compared

to 23.5% for the prior

year period.

The difference between our effective and federal statutory tax rates primarily relates to

state and

foreign income taxes and interest expense.

For the nine months ended September 27, 2025, the difference was

further impacted by the tax treatment associated with the acquisition

of a controlling interest of a previously held

non-controlling equity investment.

Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases

of additional noncontrolling

interests, repayments of debt principal, the funding of working capital needs,

purchases of fixed assets and

repurchases of common stock.

Working capital requirements generally result from increased sales, special

inventory forward buy-in opportunities and payment terms for receivables

and payables.

Historically, sales have

tended to be stronger during the second half of the year and special inventory

forward buy-in opportunities have

been most prevalent just before the end of the year, and have caused our working capital requirements

to be higher

from the end of the third quarter to the end of the first quarter of

the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt

placements.

Please see

Note 7 – Debt

for further information.

Our ability to generate sufficient cash flows from

operations is dependent on the continued demand of our customers

for our products and services, and access to

products and services from our suppliers.

Our business requires a substantial investment in working capital, which

is susceptible to fluctuations during the

year as a result of inventory purchase patterns and seasonal demands.

Inventory purchase activity is a function of

sales activity, special inventory forward buy-in opportunities and our desired level of inventory.

We finance our business to provide adequate funding for at least 12 months.

Funding requirements are based on

forecasted profitability and working capital needs, which, on occasion, may

change.

Consequently, we may change

our funding structure to reflect any new requirements.

Our acquisition strategy is focused on investments in companies,

including high growth high margin businesses

aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint

(whether entering a new country, such as emerging markets, or building scale where we have already invested in

businesses), and finally, those that enable us to access new products and technologies.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,

and our available funds under existing credit facilities provide us with

sufficient liquidity to meet our currently

foreseeable short-term and long-term capital needs.

Net cash provided by operating activities was $306 million for the

nine months ended September 26, 2026,

compared to net cash provided by operating activities of $331 million for

the prior year.

The net change of $25

million was primarily attributable to an increase in operating income, partially

offset by changes in working capital

accounts (primarily accounts receivable, inventory, and other current assets).

Net cash used in investing activities was $173 million for the nine months

ended September 26, 2026, compared to

net cash used in investing activities of $253 million for the prior year.

The net change of $80 million was primarily

attributable to lower acquisition activity.

Net cash used in financing activities was $138 million for the nine

months ended September 26, 2026, compared to

net cash provided by financing activities of $18 million for the

prior year period.

In May 2025, funds affiliated

with KKR invested $250 million in Henry Schein through the purchase

of 3,285,152 shares of common stock.

Shortly thereafter, we initiated a $250 million accelerated share repurchase program to offset the resulting dilution.

As a result, during the nine months ended September 26, 2026 we had lower

proceeds from the issuance of

common stock and lower share repurchases compared to the prior year period.

Other factors contributing to the net

change of $156 million in financing activities primarily include lower net borrowings

as well as lower payments for

acquisitions of noncontrolling interests and contingent consideration.

The following table summarizes selected measures of liquidity and capital

resources:

September 26,

December 27,

2026

2025

Cash and cash equivalents

$

$

Working

capital

(1)

1,178

1,236

Debt:

Bank credit lines

$

1,000

$

Current maturities of long-term debt

Long-term debt

2,382

2,310

Total debt

$

3,524

$

3,107

Leases:

Current operating lease liabilities

$

$

Non-current operating lease liabilities

(1)

Includes $606 million and $491 million of certain accounts receivable which serve as security for U.S. trade accounts receivable

securitization at September 26, 2026 and December 27, 2025, respectively.

Our cash and cash equivalents consist of bank balances and investments

in money market funds representing

overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations

increased to 46.6 days as of September 26, 2026

from 45.3 days as of September 27, 2025.

During the nine months ended September 26, 2026, we

wrote off

approximately $9 million of fully reserved accounts receivable against our

trade receivable reserve.

Our inventory

turns from operations decreased to 4.6 as of September 26, 2026 from 4.8

as of September 27, 2025.

Our working

capital accounts may be impacted by current and future economic conditions.

Leases

We

have operating and finance leases for corporate offices, office space, distribution and other

facilities, vehicles

and certain equipment.

Our leases have remaining terms of less than one year to approximately

22 years, some of

which may include options to extend the leases for up to 10 years.

As of September 26, 2026, our right-of-use

assets related to operating leases were $336 million and our current and

non-current operating lease liabilities were

$79 million and $288 million, respectively.

Stock Repurchases

On January 27, 2025, our Board of Directors authorized the repurchase

of up to an additional $500 million in shares

of our common stock.

On May 19, 2025, we executed an accelerated share repurchase program

to repurchase a total of $250 million of

our outstanding common stock based on volume-weighted average

prices.

In May 2025, we received 3,122,832

shares at an estimated fair value of $224

million.

In July 2025, we received an additional 368,651 shares at an

estimated fair value of $26 million, representing the final amount of shares

to be received under this accelerated

share repurchase program.

On September 8, 2025, our Board of Directors authorized the repurchase of

up to an additional $750 million in

shares of our common stock.

From March 3, 2003 through September 26, 2026, we repurchased $6.4 billion,

or 113,537,092 shares,

under our

common stock repurchase programs, with $330 million available

as of September 26, 2026 for future share

repurchases.

Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right,

at certain times, to require us to acquire

their ownership interest in those entities at fair value.

Accounting Standards Codification Topic 480-10 is

applicable for noncontrolling interests where we are or may be required

to purchase all or a portion of the

outstanding interest in a consolidated subsidiary from the noncontrolling

interest holder under the terms of a put

option contained in contractual agreements.

As of September 26, 2026 and December 27, 2025, our balance

for

redeemable noncontrolling interests was $914 million and $895 million,

respectively.

Please see

Note 12 –

Redeemable Noncontrolling Interests

for further information.

Critical Accounting Estimates

There have been no material changes in our critical accounting estimates

from those disclosed in Item 7 of our

Annual Report on Form 10-K for the year ended December 27, 2025.

Accounting Standards Update

For a discussion of accounting standards updates that have been adopted

or will be adopted, see

Note 2 - Significant

Accounting Policies, Accounting Pronouncements Recently Adopted and Recently Issued Accounting

Pronouncements

of the Notes to the Condensed Consolidated Financial Statements

included under Item 1.

Previous: Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS · Next: Item 3. QUANTITATIVE